Bayer and Evotec join hands to develop new treatments for kidney diseases

Bayer and German firm Evotec have partnered to develop to new treatments for kidney diseases.

Under the five-year, multi-target research partnership, the companies will develop several clinical candidates for the treatment of chronic kidney disease in diabetes patients.

Both parties will contribute novel drug targets and a set of technology platforms, and will share responsibilities during preclinical development.